The Ampio Pharmaceuticals (AMPE) Getting Somewhat Favorable Press Coverage, Study Shows

The Ampio Pharmaceuticals (AMPE) Getting Somewhat Favorable Press Coverage, Study Shows

News stories about Ampio Pharmaceuticals (NASDAQ:AMPE) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ampio Pharmaceuticals earned a news impact score of 0.07 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.3346193856284 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Ampio Pharmaceuticals (AMPE) traded down 1.85% during midday trading on Wednesday, reaching $1.06. The company’s stock had a trading volume of 505,354 shares. The stock has a 50 day moving average of $0.75 and a 200 day moving average of $0.64. The firm’s market capitalization is $72.33 million. Ampio Pharmaceuticals has a 52 week low of $0.38 and a 52 week high of $1.34.

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Related posts

Leave a Comment